2017
Rager JE, Auerbach SS, Chappell GA, Martin E, Thompson C , Fry RC. 2017. Benchmark dose modeling estimates of the concentrations of inorganic arsenic that induce changes to the neonatal transcriptome, proteome, and epigenome in a pregnancy cohort. Chem Res Toxicol 30(10):1911-1920; doi: 10.1021/acs.chemrestox.7b00221 . PMID: 28927277.
View Abstract
Publication: Manuscripts
2016
Rager J, Thompson C , Auerbach S, Fry R. Integrating genomic and epigenomic data into risk assessment applications through dose response modeling: Case study with prenatal arsenic exposure. Environmental Mutagenesis and Genomics Society, Kansas City, KS, September 2016.
View Abstract
Publication: Abstracts and Presentations
2014
Gentry R, Clewell H, Greene T, Franzen A , Yager J. 2014. The impact of recent advances in research on arsenic cancer risk assessment. Regul Toxicol Pharmacol 69(1):91–104; 10.1016/j.yrtph.2014.02.006 .
View Abstract
Publication: Manuscripts
2012
Boekelheide K, Blumberg B, Chapin RE, Cote I, Graziano JH, Janesick A, Lane R, Lilycrop K, Myatt L, States JC, Thayer KA, Waalkes MP, Rogers JM . 2012. Predicting later-life outcomes of early-life exposures. Environ Health Perspect 120:1353–1361; doi: 10.1289/ehp.1204934 .
View Abstract
Publication: Manuscripts
2008
Williams CW, Perry CS. Risk assessment for arsenic on indoor surfaces. Presented at the Society for Risk Analysis Annual Meeting, Boston, MA, December 2008.
